Sublingual Buprenorphine/Naloxone Tied to More Adverse Dental Outcomes

FRIDAY, Dec. 16, 2022 -- There is a higher risk for adverse dental outcomes associated with sublingual buprenorphine/naloxone compared with transdermal buprenorphine or oral naltrexone, according to a research letter published in the Dec. 13 issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news